Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 35

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

257

HTML

1941

Tables (1-6)

159

Sum=2357

Sep 21, 2006 (publication date) through Apr 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. Sep 21, 2006; 12(35): 5692-5698
Published online Sep 21, 2006. doi: 10.3748/wjg.v12.i35.5692

Table 6 Comparison of side effects in both hepatitis C groups

Variable	Group A	Group B	P
Flu-like symptoms	40 (100.0)	40 (100.0)
Discontinuation of drug	0 (0)	0 (0)	NS¹
Thyroid dysfunction	2	3	NS¹
Discontinuation of drug	1	2
Psychological upset and drug intolerability	1	1	NS¹
Discontinuation of drug	1	1
Hematological
Anemia (30% from baseline)	13 (26.0)	12 (24.0)	NS¹
Neutropenia (< 0.9 × 10⁹/L)	21 (42.0)	19 (38.0)	NS¹
Thrombocytopenia (< 50 × 10⁹/L)	None	2 (4)	NS¹

¹Not significant.

Citation: Derbala M, Kaabi SA, Dweik NE, Pasic F, Butt M, Yakoob R, Al-Marri A, Amer A, Morad N, Bener A. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage. World J Gastroenterol 2006; 12(35): 5692-5698
URL: https://www.wjgnet.com/1007-9327/full/v12/i35/5692.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i35.5692